Xiamen Amoytop Biotech Co., Ltd.

Shanghai Stock Exchange 688278.SS

Xiamen Amoytop Biotech Co., Ltd. Revenue for the year ending December 31, 2023: USD 295.83 M

Xiamen Amoytop Biotech Co., Ltd. Revenue is USD 295.83 M for the year ending December 31, 2023, a 33.70% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Xiamen Amoytop Biotech Co., Ltd. Revenue for the year ending December 31, 2022 was USD 221.26 M, a 24.17% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Revenue for the year ending December 31, 2021 was USD 178.19 M, a 46.50% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Revenue for the year ending December 31, 2020 was USD 121.63 M, a 16.08% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Revenue for the year ending December 31, 2019 was USD 104.78 M, a 60.75% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 688278.SS

Xiamen Amoytop Biotech Co., Ltd.

CEO	Mr. Li Sun
IPO Date	Jan. 17, 2020
Location	China
Headquarters	No. 330 Wengjiao Road
Employees	1,960
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Fertilizers Petrochemicals Pharmaceuticals Plastics

Description

Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.

Key trends

Past 5 years